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Abstract
OBJECTIVES—Dysbiosis leading to abnormal intestinal fermentation has been suggested as a 
possible etiological mechanism in irritable bowel syndrome (IBS). We aimed to investigate the 
location and magnitude of altered intestinal bacterial fermentation in IBS and its clinical subtypes.
METHODS—One hundred fourteen IBS patients who satisfied Rome III criteria and 33 healthy 
controls (HC) were investigated. Intestinal fermentation was assessed using two surrogate 
measures: intestinal intraluminal pH and fecal short chain fatty acids (SCFAs). Intraluminal pH 
and intestinal transit time were measured in the small and large bowel using a wireless motility 
capsule (SmartPill™) in 47 IBS and 10 HC. Fecal SCFAs including acetate, propionate, butyrate 
and lactate were analyzed by capillary gas chromatography in all enrolled subjects. Correlations 
between intestinal pH, fecal SCFAs, intestinal transit time and IBS symptom scores were 
analyzed.
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RESULTS—Colonic intraluminal pH levels were significantly lower in IBS patients compared to 
HC (total colonic pH, 6.8 for IBS vs. 7.3 for HC, P = 0.042). There were no differences in total 
and segmental pH levels in the small bowel between IBS patients and HC (6.8 vs. 6.8, P = NS). 
The intraluminal colonic pH differences were consistent in all IBS subtypes. Total SCFAs level 
was significantly lower in C-IBS patients than in D-IBS and M-IBS patients and HC. The total 
SCFAs level in all IBS subjects was similar with that of HC. Colonic pH levels correlated 
positively with colon transit time (CTT) and IBS symptoms severity. Total fecal SCFAs levels 
correlated negatively with CTT, and positively with stool frequency.
CONCLUSIONS—Colonic intraluminal pH is decreased, suggesting higher colonic 
fermentation, in IBS patients compared with HC. Fecal SCFAs are not a sensitive marker to 
estimate intraluminal bacterial fermentation.
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INTRODUCTION
Irritable bowel syndrome (IBS) is characterized by chronic or recurring abdominal pain or 
discomfort associated with altered bowel habits and is one of the most common 
gastrointestinal (GI) disorders.1, 2 IBS is considered a multifactorial disorder associated with 
visceral hypersensitivity, altered gut motility and dysfunction of the brain-gut axis and 
immune system. However, the pathophysiology of the disorder is still not completely 
understood.2–5 Recently, it has been suggested that alterations in the gut microbiota, leading 
to abnormal intestinal fermentation may be a possible etiological mechanism.6–9
Intestinal fermentation by gut microbiota is a central physiological process by which 
polymers, including carbohydrates, are biotransformed into end-products, mainly short chain 
fatty acids (SCFAs) and gases. These intra-luminal fermentation processes have an 
important role in supplying nutrients and energy to the host.10 However, alterations in 
intestinal fermentation may lead to certain physiological abnormalities that are often 
observed in IBS such as intraluminal excessive gas production and altered motility. These 
alterations in intestinal physiology can be an important factor in provoking or exacerbating 
IBS symptoms.11, 12 In addition, interventional clinical studies targeting the intestinal 
microbiota with antibiotics or probiotics demonstrated beneficial effects in some patients 
with IBS. 19, 20Specifically, in regard to intestinal fermentation, recent studies have shown 
that diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols 
(FODMAPs) can offer considerable symptom relief in patients with IBS.13, 14 However, the 
role of altered intestinal fermentation by intestinal bacteria in the pathogenesis of IBS has 
not been adequately investigated in this condition.
We hypothesized that bacterial fermentation is altered in certain segments of the GI tract in 
IBS, and that these alterations are associated with bowel functions and symptoms. The aims 
of the current study were to investigate the location and magnitude of altered intestinal 
bacterial fermentation in IBS and its clinical subtypes, and to examine their relation to bowel 
characteristics and GI symptoms. Intestinal fermentation was assessed by measuring 
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intraluminal pH levels [by a wireless motility capsule (SmartPill™)] and fecal SCFAs 




All subjects were recruited from the University of North Carolina (UNC) healthcare 
outpatient clinics and from the Chapel Hill general population by advertising. Inclusion 
criteria included age of 18 years or older, any gender, race, or ethnicity. Healthy controls had 
no chronic or recurring GI symptoms. IBS patients met the Rome III criteria for IBS and had 
mild to moderate symptom severity with IBS-symptom severity scale (IBS-SSS) score of 
175–300. Additional inclusion criteria included normal physical examination and laboratory 
tests and a normal colonoscopy within the last 3 years, in patients age 50 or older. Subjects 
with a history of GI tract surgery (other than appendectomy or cholecystectomy), a history 
of inflammatory bowel diseases (IBD), celiac disease, lactose malabsorption, or any other 
diagnosis that could explain their chronic or recurrent bowel symptoms were excluded from 
the study. In addition, participants were excluded if they had a history of treatment with 
antibiotics, anti-inflammatory agents including aspirin, non-steroidal anti-inflammatory 
drugs or steroids, or intentional consumption of probiotics in the past 6 weeks. All subjects 
were evaluated by a physician to exclude an alternative diagnosis to IBS. The study was 
approved by the UNC Internal Review Board (IRB) and all subjects provided written 
consent before participation and were compensated for participating in the study.
Clinical symptom assessments in IBS
Abdominal pain/discomfort, altered bowel habit (loose/watery or hard/lumpy stools), and 
bloating were assessed using a 10-cm visual analogue scale (VAS; maximum score, 10).15 
IBS symptom severity scale (IBS-SSS)16 and IBS specific quality of life (IBS-QOL)17 were 
also assessed. Stool frequency was measured by number of bowel movements per day and 
stool consistency determined using the stool Bristol Score.18
Assessment for intraluminal fermentation and intestinal transit
Intestinal fermentation was assessed using two surrogate markers: Intestinal intraluminal pH 
and fecal SCFAs. Intraluminal pH levels were measured using a wireless motility capsule 
(SmartPill™; Given Imaging, Yoqneam, Israel). The wireless motility capsule is an FDA 
approved device that is clinically used to assess intestinal transit. After being swallowed, the 
capsule constantly measures intraluminal pH, pressure, and temperature as it travels through 
the GI tract and transmits this information wirelessly to a portable receiver worn by the 
examinee.19 Using these parameters and a specific software the (SmartPill™) system 
generate data on gastric emptying time (GET), small bowel transit time (SBTT), colon 
transit time (CTT) and whole gut transit time (WGTT).19, 20 For the purpose of this study 
we used the intraluminal pH data as surrogate markers for intestinal fermentation. To enable 
further accuracy in assessment of localization of intestinal fermentation, the small and large 
bowel pH measurements were both divided into four quartiles (Q1–4) based on the total time 
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in each (small and large bowel) segment. SBTT, CTT, and WGTT were also assessed as 
previously described.19, 20
Analysis of SCFA
Fresh stool samples were collected from all subjects on site or at home in the morning of the 
study visit. Each fecal sample was immediately transferred to the laboratory where it was 
homogenized and stored at −80°C until analyzed. Fecal acetate, propionate, butyrate, lactate 
and total SCFAs were quantified in fecal samples in duplicate using capillary gas 
chromatography with 2-ethyl butyric acid as an internal standard, as described 
previously.10, 21–23
Statistical Analysis
We used Student t-test when there were two groups being compared and analysis of variance 
(ANOVA) when there were more than two groups being compared for continuous variables. 
The chi-square test was used for discrete variables. For post hoc analysis, Tukey’s honest 
significance test was used. Baseline characteristics were evaluated by Student t-test or 
Pearson’s chi-square test. Intestinal pH, fecal SCFAs levels and GI transit times were 
compared between groups by Student t-test or ANOVA. Correlations between colonic pH, 
fecal SCFAs, CTT, stool frequency and consistency, IBS-SSS, and IBS-QOL were done 
using Spearman correlation analysis for all study subjects including IBS and HC. All P 
values were two-tailed, and P values < 0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS version 18.0 for Windows (SPSS, Inc., 




We investigated a total of 147 subjects (114 IBS and 33 HC). The study IBS population 
included patients with constipation-predominant IBS (C-IBS, n=26), diarrhea-predominant 
IBS (D-IBS, n=42), mixed type IBS (M-IBS, n=32) and unspecified type IBS (U-IBS, 
n=14). The racial distribution was as follows: Caucasian 70.7%, Black 21.1%, and other 
8.2%. There were no significant differences in age, sex, body mass index, and race between 
the study groups (Table 1).
Intestinal intraluminal pH
Intestinal intraluminal pH data were collected from 47 patients with IBS and 10 HC. Mean 
total colonic pH levels were significantly lower in the IBS group compared to HC (6.8 vs. 
7.3, P = 0.042). The significant differences were also observed in Q1 (6.4 vs. 6.8, P = 0.011) 
and Q4 (7.2 vs. 7.8, P = 0.046). The colonic pH levels at the first quartile (Q1) were the 
lowest among the four quartiles in both groups (Table 2 and Fig. 1). The lower intraluminal 
colonic pH levels compared to HC were consistent across all IBS subtypes (mean total 
colonic pH: 7.0 for C-IBS, 7.0 for D-IBS, 6.8 for M-IBS, 6.4 for U-IBS, and 7.3 for HC, 
respectively) (Table 3).
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There were no intraluminal pH differences in the 4 quartiles and total small bowel between 
IBS and HC (mean total small bowel pH: 6.8 for IBS vs. 6.8 for HC, P = 0.937) (Table 2). 
Also, there were no significant intraluminal small bowel pH differences between the groups 
based on IBS subtypes.
In subgroup analyses, small and large bowel pH levels were not different according to 
gender, race and age (≤ 45 vs. > 45).
Fecal short chain fatty acids
Fecal SCFAs were measured in all enrolled subjects (114 IBS and 33 HC). Mean acetate, 
propionate, butyrate, lactate and total fecal SCFAs levels were not significantly different 
between all IBS and HC (total SCFAs level: 92.1 mM vs. 92.0 mM, P = 0.996, respectively). 
Acetate had the highest levels followed by propionate and butyrate in both IBS and HC. 
Lactate was not detected except for two cases (6.4 mM in a M-IBS subject and 8.1 mM in a 
D-IBS subject). The SCFAs profiles were similar across the different IBS subtypes (Table 4 
and Fig. 2). However, acetate, propionate, butyrate, and total SCFAs levels were lower in C-
IBS than in all the other subtypes, and were significantly lower compared to D-IBS. The 
propionate level in C-IBS was significantly lower than in any other group.
Intestinal transit time
Intestinal transit time data were collected from 47 patients with IBS and 10 HC. Overall the 
average intestinal transit times including SBTT, CTT, and WGTT were not significantly 
different between IBS patients and HC. However, as expected, CTT and WGTT were 
significantly longer in C-IBS than those in D-IBS and M-IBS. There were no significant 
differences in SBTT between the groups. The whole gut and segmental transit times are 
presented in Table 5.
Correlation between colonic pH, fecal SCFAs, CTT and symptoms
Colonic pH levels positively correlated with CTT (Spearman correlation coefficient, SCC = 
0.33, P = 0.013), and had a negative correlation trend with fecal SCFAs levels (SCC = −0.23, 
P = 0.079). Acetate, propionate, butyrate and total SCFAs levels correlated negatively with 
CTT, and positively with stool frequency (total SCFAs vs. CTT, SCC = −0.44, P = 0.001; 
total SCFAs vs. stool frequency, SCC = 0.45, P < 0.001).
Colonic pH levels positively correlated with IBS-SSS (SCC = 0.49, P = 0.014), and similar 
positive trends were noted for abdominal pain and bloating with negative trends for IBS-
QOL. CTT had correlation trend positively with IBS symptom scores and negatively with 
IBS-QOL. Fecal SCFAs levels had no correlation with IBS symptom scores and QOL. The 
results of Spearman correlation analyses are presented in Table 6.
DISCUSSION
IBS is a common condition that affects nearly 10% of the general population,1, 2 and 
contributes to a significant decrease in quality of life along with an increase in healthcare 
utilization. In spite of its high prevalence and impact on quality of life, the 
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pathophysiological mechanisms underlying the disease remains unknown. Recently, the 
possible role of the intestinal microbiota in the pathogenesis of IBS has gained much 
interest.4, 8, 24 In this study, we investigated the role of intestinal bacterial fermentation in 
IBS.
Intraluminal intestinal fermentation by colonic bacteria produces gases such as hydrogen 
and carbon dioxide, and SCFAs as secondary by-products.10, 25, 26 The predominant SCFAs 
produced by bacterial fermentation are acetate, butyrate, and propionate. Lactate, which is a 
precursor for propionate and butyrate, is itself a by-product of fermentation. SCFAs are 
naturally acidic and cause a measurable drop in the pH of the intestinal lumen.26–28 In this 
study we have measured intraluminal pH levels and fecal SCFA concentrations as surrogate 
markers for intraluminal intestinal fermentation and used these factors to assess the location 
and magnitude of intestinal bacterial fermentation in a well characterized cohort of patients 
with IBS and HC.
We found that the mean total colonic pH levels were significantly lower in IBS compared to 
HC potentially indicating higher intraluminal bacterial fermentation in the IBS group. Of 
great importance is our finding of consistently higher bacterial fermentation in the large 
bowel of patients with IBS compared to HC while there were no differences in the pH levels 
in the small bowel between those two groups. Notably these findings were consistent in all 
small bowel and large bowel segments and across all IBS subtypes.
The intraluminal pH levels were lower at the proximal colon than the distal colon in both 
IBS and HC groups when we divided the quartiles based on the transit time. However, the 
quartiles based on transit time might not be the same with those based on geography, 
because if some patients might have mixtures of very rapid transit through one part of the 
colon, and then very slow transit through the next, although these two segments might differ 
pathophysiologically. Although those cases were not considered common findings, it may be 
a limitation of our study.
Small intestinal bacterial overgrowth (SIBO) is a condition in which an excess of colonic 
bacteria colonize the small intestine. The symptoms of SIBO and IBS overlap29 and it has 
been suggested that the prevalence of SIBO is increased in IBS or that SIBO may have an 
etiological role in the pathogenesis of IBS, particularly in view of the improvement of 
symptoms with antibiotic treatment.30–33 However, the link between SIBO and IBS is still 
unclear and there are some controversies regarding the real prevalence and the importance of 
SIBO in the pathogenesis of IBS.34 Our study findings indicate an increased bacterial 
fermentation in the large but not in the small bowel of patients with IBS, thus supporting the 
hypothesis of altered microbial composition and/or function in the colon rather than in the 
small bowel (e.g., in SIBO) in the pathogenesis of IBS. In addition, our finding of significant 
differences in total and segmental CTT but not in SBTT between IBS and its subtypes and 
HC, further support the importance of altered colonic- rather than small bowel physiology in 
the pathogenesis of the disorder.
The importance of SCFAs as possible etiological factors in the pathogenesis of IBS is 
suggested by observations from animal and human studies. Animal studies demonstrate that 
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SCFA can initiate high-amplitude propagated colonic contractions35 and accelerated 
intestinal transit and motility via intestinal release of 5-hydroxytryptamine.36 Intracolonic 
infusion of 0.5% acetic acid enhanced sensitivity to colorectal distension.37 In a human 
study, the total concentration of SCFAs in jejunal secretion was approximately four times 
higher in patients with SIBO than in healthy subjects.38 In addition, a recent study reported 
higher counts of acetic- and propionic-acid producing bacteria (Veillonella and 
Lactobacillus) in IBS patients and an association between the higher levels of these SCFAs 
and GI symptoms and QOL.39 However, the studies in this area have generated conflicting 
findings on fecal organic acids. For example, a study conducted in patients with D-IBS 
showed that fecal SCFAs were decreased compared to HC.40 In our study, there were no 
significant differences in the mean levels of fecal SCFAs between IBS (all subtypes) and HC 
and the levels of fecal SCFAs did not correlate with IBS symptom severity. However, we 
were able to demonstrate that fecal SCFAs levels in C-IBS patients were significantly lower 
than in D-IBS patients, and tended to be lower than those in all the other IBS subtypes and 
HC. In addition, as expected, SCFAs levels negatively correlated with CTT which is 
consistent with our finding of a positive correlation between colonic pH and CTT, indicating 
that higher fermentation with higher production of SCFA is associated with increased 
motility and shorter transit times. An alternative explanation can be reduced absorption of 
SCFAs in patients with rapid intestinal transit due to a shorter transit time. The difficulties in 
interpretation of these findings reflect the multifactorial determinants of fecal SCFAs. 
Intraluminal SCFAs are very efficiently absorbed in the colon and only 5% to 10% of the 
SCFAs produced by bacterial fermentation are excreted and can be measured in the 
stool.41–43 The correlation between fecal SCFAs levels and CTT and the differences 
between IBS subtypes suggest that fecal SCFAs levels may be controlled by CTT more 
dominantly than fermentation degree, thus, fecal SCFAs may not be a sensitive marker to 
estimate intraluminal bacterial fermentation.
In addition to magnitude and location, we examined the associations between intestinal 
fermentation and clinical presentation of IBS. Unlike what we expected the colonic pH 
levels positively correlated with IBS symptom scores including IBS-SSS. This finding 
suggests that other factors such as abnormal intestinal motility and psychological 
disturbances may be more important than bacterial fermentation in determining symptoms 
severity.
The wireless motility SmartPill™ capsule measures pH, pressure and temperature in real 
time throughout the GI tract.19 Overall, pH profiles in the GI tract are characterized by an 
abrupt rise in pH from acid to near neutral as the capsule exited the stomach, a slow 
continued rise in pH through the small bowel until reaching the large bowel where pH falls 
more than 1 unit, and subsequently, there is a slow rise in pH through the colon.19, 44 The pH 
drop at the ileocecal junction is well documented in studies using ingestible radiotelemetry 
capsules.45, 46 Time between an abrupt rise of pH in duodenum and a fall of >1 pH unit in 
ileocolonic junction was taken as SBTT. CTT was assessed by measuring the time required 
from cecal entry to body exit (loss of signal and/or an abrupt temperature drop).19 A recent 
scintigraphic study using a radioisotope-labeled WMC has validated this pH change at the 
ileocolonic junction and has shown that the fall in pH observed with WMC corresponds to 
the time of arrival of the WMC into the cecum or ascending colon.47 Several studies have 
Ringel-Kulka et al. Page 7













confirmed the utility of WMC in quantifying CTT when compared to radiopaque marker 
method. There was good agreement between the WMC and radiopaque marker transit 
results.20, 44 The WMC is a validated test, however there are some confounding issues with 
the test. The pH drop at the ileocecal junction is occasionally (<5%) not clearly identifiable, 
and device failure is reported in <3% of cases. In our study, the pH landmarks were well 
identified in all cases and there were no capsule failures.
To our knowledge there has been no previous study to evaluate bacterial fermentation in the 
whole intestine by assessing intraluminal pH changes in patients with IBS. However, our 
study may have some limitations. Firstly, although subjects were asked to keep their regular 
diet during the study, we did not have detailed dietary data and could not control for dietary 
effects on intestinal physiology and fermentation processes including intraluminal pH and 
SCFAs production. Second, we did not investigate the intestinal bacterial community, so we 
do not know which bacterial species or genera were altered and how these alterations relate 
to the variables of interest. Third, we did not evaluate gas production, such as hydrogen and 
methane which might be associated with symptom generation. Finally, the analyses of the 
wireless motility capsule (SmartPill™) data included a relatively small number of subjects 
and involved some multiple comparisons; particularly in sub-analysis by IBS subtypes. 
Further large scale studies, including the analyses of dietary factors, gas production and 
bacterial communities are needed. These studies may enable to associate alterations in 
bacterial fermentation with specific diet or bacterial communities and provide insights on 
how these associations relate to the altered physiology and symptoms observed in IBS.
In conclusion, we found that colonic intraluminal pH is decreased, suggesting increased 
bacterial fermentation, in IBS patients across all subtypes compared with HC, and that this 
process is more prominent in the proximal colon. The altered intestinal fermentation and 
transit in IBS appear to be in the colon and not in the small bowel. Higher levels of fecal 
SCFAs and lower levels of intraluminal pH are associated with decreased CTT. The 
hypothesized model of our study results was illustrated in the figure 3. Our study further 
support the notion that altered colonic bacterial fermentation has an important etiological 
role for in the pathogenesis of IBS. Future studies should investigate the degree to which 
altered intestinal fermentation is a cause of IBS symptoms or an effect of IBS-related altered 
physiology by, if possible, direct measurement of bacterial fermentation, and clarify the 
possible clinical benefit of targeting intestinal fermentation in the treatment of functional GI 
disorders.
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WHAT IS CURRENT KNOWLEDGE
✓ Alterations in the gut microbiota play a role in irritable bowel syndrome 
(IBS).
✓ Alterations in intestinal fermentation lead to certain physiological 
abnormalities such as intraluminal excessive gas production and altered 
motility.
✓ Diet low in fermentation substrates such as poorly absorbable, highly 
fermentable carbohydrates offer considerable symptom relief in IBS.
✓ The understanding of the role of altered intestinal fermentation, including 
its magnitude and location, in the pathogenesis of IBS is not completely 
understood.
WHAT IS NEW HERE
✓ Colonic intraluminal pH decreased, indicating higher intestinal 
fermentation, in IBS patients across all subtypes compared with healthy 
controls.
✓ The intestinal fermentation in IBS is altered in the colon but not in the small 
bowel.
✓ Higher levels of fecal SCFAs and lower levels of intraluminal pH are 
associated with decreased colon transit time.
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Colonic pH levels. Quartile 1 and 4, and mean total colonic pH levels were significantly 
lower in irritable bowel syndrome (n=47) compared to healthy control (n=10). The pH in the 
proximal colon (quartile 1) was the lowest in both groups. * P < 0.05
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Fecal short chain fatty acids (SCFAs) levels by irritable bowel syndrome subtypes. Total 
SCFAs level was significantly lower in constipation-predominant irritable bowel syndrome 
(C-IBS) than in diarrhea-predominant IBS, mixed type IBS and healthy control (HC). Total 
SCFAs level averaged across all IBS was similar with that in HC. Propionate level in C-IBS 
was significantly lower than those of the other groups. Acetate and butyrate levels were 
significantly lower in C-IBS than in D-IBS. * P < 0.05.
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Hypothesized model. Colonic intraluminal pH is decreased and SCFAs production is 
increased suggesting higher fermentation in patients with IBS compared with HC. SCFAs 
are effectively absorbed (> 95% of SCFAs) in the GI tract and only a small portion (~5% of 
total SCFAs) is excretion in feces. Both processes can affect and are affected by intestinal 
transit. Abbreviations: SCFAs, short chain fatty acids; IBS, irritable bowel syndrome; HC, 
healthy control.
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Table 1
Baseline characteristics of the study groups
IBS HC P - value
Number of subjects 114 33
Age (years): mean 35.4±11.3 33.9±13.0 0.534
Sex (male:female) 16:98 4:29 0.778
Body mass index (kg m−2): mean 27.1±5.5 27.2±9.2 0.929
Race 0.054
   Caucasian 84 (73.7%) 20 (60.6%)
   Black 24 (21.1%) 7 (21.2%)
   Others 6 (5.3%) 6 (18.2%)
IBS subtype: number
  Constipation-predominant 26 (22.8%)
 Diarrhea-predominant 42 (36.8%)
   Mixed type 32 (28.1%)
 Unspecified type 14 (12.3%)
IBS; irritable bowel syndrome, HC; healthy control
The data are presented as mean ± standard deviation.
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Table 2







 Q1 small bowel pH 6.1±0.7 6.2±1.0 0.885
 Q2 small bowel pH 6.7±0.5 6.7±0.4 0.840
 Q3 small bowel pH 7.1±0.4 7.1±0.4 0.994
 Q4 small bowel pH 7.3±0.4 7.3±0.5 0.878
 Total small bowel pH 6.8±0.4 6.8±0.4 0.937
Colonic pH
 Q1 Colonic pH 6.4±0.6 6.8±0.4 0.011
 Q2 Colonic pH 6.8±0.7 7.1±0.5 0.173
 Q3 Colonic pH 7.0±0.8 7.5±0.6 0.081
 Q4 Colonic pH 7.2±0.8 7.8±0.8 0.046
 Total Colonic pH 6.8±0.7 7.3±0.5 0.042
IBS; irritable bowel syndrome, HC; healthy control, Q; quartile
The data are presented as mean ± standard deviation.
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